Cargando…

Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro

BACKGROUND: Advanced or metastatic renal cell carcinoma (RCC) has a poor prognosis, because it is relatively resistant to conventional chemotherapy or radiotherapy. Treatments with human interferon-α2b alone or in combination with mammalian target of rapamycin (mTOR) inhibitors have led to only a mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardillo, Thomas M, Trisal, Preeti, Arrojo, Roberto, Goldenberg, David M, Chang, Chien-Hsing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623828/ https://www.ncbi.nlm.nih.gov/pubmed/23548153 http://dx.doi.org/10.1186/1471-2407-13-170

Ejemplares similares

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Evaluation of a Novel Hexavalent Humanized Anti-IGF-1R Antibody and Its Bivalent Parental IgG in Diverse Cancer Cell Lines
por: Chang, Chien-Hsing, et al.
Publicado: (2012)

IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients
por: Erbay, Ebru, et al.
Publicado: (2003)

IGF1-Stimulated Posttraumatic Hippocampal Remodeling Is Not Dependent on mTOR
por: Littlejohn, Erica L., et al.
Publicado: (2021)

Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver
por: Spormann, Luise, et al.
Publicado: (2020)

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma
por: Kling, Matthew J., et al.
Publicado: (2021)

Tissue-Specific Responses of IGF-1/Insulin and mTOR Signaling in Calorie Restricted Rats
por: Sharma, Naveen, et al.
Publicado: (2012)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Optimising the use of mTOR inhibitors in renal transplantation
por: Russ, Graeme R
Publicado: (2013)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Combined HASPIN and mTOR inhibition is synergistic against KRAS-driven carcinomas
por: Xu, Chenyue, et al.
Publicado: (2022)

Matrix IGF-1 regulates bone mass by activation of mTOR in mesenchymal stem cells
por: Xian, Lingling, et al.
Publicado: (2012)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth
por: Soliman, Ghada A, et al.
Publicado: (2020)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells
por: Grabinski, Nicole, et al.
Publicado: (2012)

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells
por: Kim, Hyera, et al.
Publicado: (2020)

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells
por: Reita, Damien, et al.
Publicado: (2019)

The Interfaces Between Signal Transduction Pathways: IGF-1/mTor, p53 and the Parkinson Disease Pathway
por: Levine, Arnold J., et al.
Publicado: (2012)

The Effects of Exogenous Lactate Administration on the IGF1/Akt/mTOR Pathway in Rat Skeletal Muscle
por: Kyun, Sunghwan, et al.
Publicado: (2020)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma
por: Hubert, Jean-Noël, et al.
Publicado: (2021)

mTOR Signaling Pathway in Cancer Targets Photodynamic Therapy In Vitro
por: Ayuk, Sandra M., et al.
Publicado: (2019)

Additive effects of inhibiting both mTOR and glutamine metabolism on the arthritis in SKG mice
por: Ueda, Yo, et al.
Publicado: (2019)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014)

mTOR, autophagy, and reprogramming
por: Tang, Bor Luen
Publicado: (2014)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

mTOR in cerebrovascular disease
por: Van Skike, Candice E., et al.
Publicado: (2019)

mTOR and Tumor Cachexia
por: Duval, Adrian P., et al.
Publicado: (2018)

Double agent mTOR
por: Danzer, Steve C.
Publicado: (2019)

mTOR in Human Diseases
por: Dormond, Olivier
Publicado: (2019)

Preconceptional Lipid-Based Nutrient Supplementation in 2 Low-Resource Countries Results in Distinctly Different IGF-1/mTOR Placental Responses
por: Castillo-Castrejon, Marisol, et al.
Publicado: (2020)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

MK-2206 Alleviates Renal Fibrosis by Suppressing the Akt/mTOR Signaling Pathway In Vivo and In Vitro
por: Chen, Meiling, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ung0gbpao6otidf9icie8cmfs